Sugi Predict

Sugi Predict / Targets / BRD7

BRD7

Bromodomain-containing protein 7 · Q9NPI1 · BRD7 on Sugi Atlas →

9,951 patent compounds predicted against BRD7, 6,741 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Hydrochloric Acid Hydrochloric Acid (SCHEMBL5317549) 0.60 8/20
SCHEMBL6710912 SCHEMBL6710912 0.46 4/20
SCHEMBL8275696 SCHEMBL8275696 0.46 4/20
SCHEMBL8476265 SCHEMBL8476265 0.40 4/20
SCHEMBL8275580 SCHEMBL8275580 0.40 4/20
SCHEMBL1719807 SCHEMBL1719807 0.59 3/20
SCHEMBL194469 SCHEMBL194469 0.39 3/20
SCHEMBL6412872 SCHEMBL6412872 0.38 3/20
SCHEMBL7990694 SCHEMBL7990694 0.35 3/20
SCHEMBL5800402 SCHEMBL5800402 0.35 3/20
SCHEMBL7504851 SCHEMBL7504851 0.32 3/20
SCHEMBL10242038 SCHEMBL10242038 0.83 2/20
SCHEMBL4911375 SCHEMBL4911375 0.82 2/20
SCHEMBL4911386 SCHEMBL4911386 0.82 2/20
SCHEMBL279905 SCHEMBL279905 0.75 2/20
SCHEMBL5534287 SCHEMBL5534287 0.67 2/20
Sulfasalazine Sulfasalazine (SCHEMBL4514) 0.65 2/20
Sulfasalazine Sulfasalazine (SCHEMBL4515) 0.65 2/20
Sulfasalazine Sulfasalazine (SCHEMBL487664) 0.65 2/20
SCHEMBL5582342 SCHEMBL5582342 0.65 2/20

Clinical trials — most relevant to BRD7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD PHASE3COMPLETED
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors PHASE1/PHASE2RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma PHASE1/PHASE2RECRUITING
Vorinostat in Children PHASE1/PHASE2COMPLETED
Chidamide Combined With Toripalimab in Sarcoma PHASE2COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma PHASE2COMPLETED
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation PHASE2UNKNOWN
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of SYHA1801 Monotherapy in Patients With Advanced Solid Tumors PHASE1UNKNOWN
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer PHASE1RECRUITING
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies PHASE1RECRUITING
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers PHASE1COMPLETED
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer PHASE1RECRUITING
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma EARLY_PHASE1RECRUITING
Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor nanNO_LONGER_AVAILABLE
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Autophagy Bladder Cancer nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia nanRECRUITING
Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a BRD7 binder may also engage these)

ProteinNameSimilarity
Q5R8B0 — 1.000 Q5R8B0 →
O88665 — 1.000 O88665 →
Q6GLP7 — 1.000 Q6GLP7 →
Q5ZKG2 — 0.998 Q5ZKG2 →
Q3UQU0 — 0.994 Q3UQU0 →
Q7ZUF2 — 0.992 Q7ZUF2 →
Q6DD45 — 0.992 Q6DD45 →
SMARCC2 SWI/SNF complex subunit SMARCC2 0.991 landscape →
Q9ULJ8 — 0.991 Q9ULJ8 →
Q6NVM8 — 0.991 Q6NVM8 →
Q92613 — 0.991 Q92613 →
A8DZJ1 — 0.991 A8DZJ1 →
BRD9 Bromodomain-containing protein 9 0.991 landscape →
Q9Z277 — 0.990 Q9Z277 →
E7F7X0 — 0.990 E7F7X0 →
NFRKB Nuclear factor related to kappa-B-binding protein 0.990 landscape →
Q7ZXV6 — 0.990 Q7ZXV6 →
Q3UB74 — 0.990 Q3UB74 →
Q7Z3E5 — 0.990 Q7Z3E5 →
Q1LYM3 — 0.990 Q1LYM3 →
D4AEC2 — 0.990 D4AEC2 →
Q8WML3 — 0.990 Q8WML3 →
SMARCC1 SWI/SNF complex subunit SMARCC1 0.989 landscape →
Q9JHU2 — 0.989 Q9JHU2 →
Q9CYA6 — 0.989 Q9CYA6 →
Q9DDT2 — 0.989 Q9DDT2 →
P61406 — 0.989 P61406 →
BAZ1A Bromodomain adjacent to zinc finger domain protein 1A 0.989 landscape →
A6QP06 — 0.989 A6QP06 →
Q8BMD7 — 0.989 Q8BMD7 →